RM 718
Alternative Names: RM-718Latest Information Update: 20 Jan 2025
At a glance
- Originator Rhythm
- Class Obesity therapies
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity
Most Recent Events
- 20 Jan 2025 9433831 - KDM updated
- 01 Jun 2024 Pharmacodynamics and adverse events data from a preclinical study in Obesity presented at the 106th Annual Meeting of the Endocrine Society (ENDO-2024)
- 05 Mar 2024 Phase-I clinical trials in Obesity (In adolescents, In adults, In the elderly) in USA (SC) (NCT06239116)